Viking Therapeutics' stock fell over 42% in a single day, driven by market misgivings despite the company’s VK2735 drug achieving notable weight loss results comparable to Eli Lilly’s offerings. Analysts deem the sell-off unwarranted, highlighting Viking's promising drug safety and potential as a disruptor in an increasingly competitive GLP-1 market. Investors are seeing Viking’s significantly undervalued stock as a buying opportunity amidst a landscape dominated by Eli Lilly and Novo Nordisk, which continue to generate strong sales.
“VK2735 · achieved weight loss results similar to · Eli Lilly's drug · 12% body weight loss”
“Viking Therapeutics · stock plummeted · more than 40% · in a single day”
“Viking's sell-off · was not warranted”
“Shares of Viking Therapeutics · crashed · 42% · in a single day”
“Viking's drug · was · safe and well-tolerated”
“Viking's stock · is cheap enough that I think the upside vastly outweighs · the risk”
“VK2735 · could obtain approval · next few years”
“VK2735 · did well in · phase 2 trial · helped people lose around 15% of their body weight after 13 weeks”
“Viking Therapeutics · wasn't one of · the 10 best stocks · identified by the Motley Fool Stock Advisor”
“Stock Advisor’s total average return · is · 1,056%”
“GLP-1 market · has been in the spotlight for · the past couple of years · multi-billion-dollar potential”
“Novo Nordisk · currently dominates · GLP-1 market · true”
